Genomic aberrations and survival in chronic lymphocytic leukemia.
paper
Cited
Public
Unavailable
- Authors
- Döhner, H; Stilgenbauer, S; Benner, A; Leupolt, E; Kröber, A; Bullinger, L; Döhner, K; Bentz, M; Lichter, P
- Year
- 2000
- Journal
- The New England journal of medicine
- PMID
- 11136261
- DOI
- 10.1056/NEJM200012283432602
BACKGROUND: Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and assessed their prognostic implications. METHODS: Mononuclear cells from the blood of 325 patients with chronic lymphocytic leukemia were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 6q21, 11q22-23, 13q14, and 17p13; trisomy of bands 3q26, 8q24, and 12q13; and translocations involving band 14q32. Molecular cytogenetic data were correlated with clinical findings. RESULTS: Chromosomal aberrations were detected in 268 of 325 cases (82 percent). The most frequent changes were a deletion in 13q (55 percent), a deletion in 11q (18 percent), trisomy of 12q (16 percent), a deletion in 17p (7 percent), and a deletion in 6q (7 percent). Five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; the median survival times for patients in these groups were 32, 79, 114, 111, and 133 months, respectively. Patients in the 17p- and 11q-deletion groups had more advanced disease than those in the other three groups. Patients with 17p deletions had the shortest median treatment-free interval (9 months), and those with 13q deletions had the longest (92 months). In multivariate analysis, the presence or absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the serum lactate dehydrogenase level, and the white-cell count gave significant prognostic information. CONCLUSIONS: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival. These findings have implications for the design of risk-adapted treatment strategies.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia. | Carrillo-Serradell L et al. | — | 2026 | → |
| Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes. | Abdelmoaty M et al. | — | 2026 | → |
| Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. | Martino EA et al. | — | 2026 | → |
| Molecularly targeted therapy and immunotherapy in leukemias. | Cousin E et al. | — | 2026 | → |
| On the uses and abuses of biomarkers in clinical reasoning. | Chin-Yee B | — | 2026 | → |
| Optical Genome Mapping Enhances Structural Variant Detection and Refines Risk Stratification in Chronic Lymphocytic Leukemia. | Chakraborty SR et al. | — | 2026 | → |
| Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features. | Marco-Ayala J et al. | — | 2026 | → |
| The ABCs of IGHV Testing in Chronic Lymphocytic Leukaemia: Current Recommendations, Ongoing Challenges, and Future Directions. | Wood RK et al. | — | 2026 | → |
| What does BCL-2 do? From new molecular insights to the clinical implications. | Croce CM et al. | — | 2026 | → |
| Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies. | Tam CS et al. | — | 2026 | → |
| Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia. | Shao Q et al. | — | 2025 | → |
| Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial. | Simon F et al. | — | 2025 | → |
| "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel therapies. | Vadasz B et al. | — | 2025 | → |
| Advances in the combination of CAR-T therapy with small-molecule reagents for hematologic malignancies. | Yang B et al. | — | 2025 | → |
| An analysis of 100 patients with chronic lymphocytic leukemia in Kerbala, Iraq: a comprehensive immunophenotypic and genetic study | Al-Saadi EAKD | — | 2025 | — |
| An Incidental Finding of Gain of a Diminished Chromosome 12 Centromere in an Individual with Lymphocytosis: A Case Report and Clinical Implications in Cytogenetic Testing. | Xia C et al. | — | 2025 | → |
| Association of Galectin-9 Soluble Immune Checkpoint with Clinical Prognostic Markers in Patients with Chronic Lymphocytic Leukemia. | Ntsethe A et al. | — | 2025 | → |
| ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker. | Thorvaldsdottir B et al. | — | 2025 | → |
| A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease. | Young C et al. | — | 2025 | → |
| Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia. | Iatrou A et al. | — | 2025 | → |
| Back from (BTKi) holiday. | Brander DM et al. | — | 2025 | → |
| B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies. | Patil S et al. | — | 2025 | → |
| BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia. | Chong SJF et al. | — | 2025 | → |
| Case Report: Unraveling complex genomic alterations in a case of chronic lymphocytic leukemia using optical genome mapping. | Youssefian L et al. | — | 2025 | → |
| Chromoanagenesis Detection in Chronic Lymphocytic Leukemia. | Ramos-Campoy S et al. | — | 2025 | → |
| Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. | Hallek M | — | 2025 | → |
| Chronic lymphocytic leukemia: criteria for first-line therapeutic choice-an opinion paper. | Carda J et al. | — | 2025 | → |
| Chronic Lymphocytic Leukemia: Investigation of Survival and Prognostic Factors with Drug-Related Remission. | Pektaş G et al. | — | 2025 | → |
| Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma. | Zhang X et al. | — | 2025 | → |
| Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel. | Alotaibi G et al. | — | 2025 | → |
| Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy. | Kharfan-Dabaja MA et al. | — | 2025 | → |
| Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways. | Caputo C et al. | — | 2025 | → |
| Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. | Soumerai JD et al. | — | 2025 | → |
| Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. | Pavlova S et al. | — | 2025 | → |
| Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH). | Chiattone CS et al. | — | 2025 | → |
| Downregulation of miRNA-133a and miRNA-452 associated with upregulation of CLNK and LEF1 genes in chronic lymphocytic leukemia: in vitro and in silico insights. | Dalyan A et al. | — | 2025 | → |
| Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series. | Goergen E et al. | — | 2025 | → |
| Exceptional Response to Fixed Duration Obinutuzumab and Venetoclax in a Patient with Chronic Lymphocytic Leukemia: A Case Report. | Rosenberg M et al. | — | 2025 | → |
| Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study. | Fresa A et al. | — | 2025 | → |
| Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. | Burger JA et al. | — | 2025 | → |
| Greek Consensus on Chronic Lymphocytic Leukemia (CLL) Treatment. | Sachanas S et al. | — | 2025 | → |
| [Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)]. | Medina Á et al. | — | 2025 | → |
| Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. | Langerbeins P et al. | — | 2025 | → |
| Impact of biological and genetic features of leukemic cells on the occurrence of "shark fins" in the WPC channel scattergrams of the Sysmex XN hematology analyzers in patients with chronic lymphocytic leukemia. | Egger M et al. | — | 2025 | → |
| Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work-Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping. | Kanagal-Shamanna R et al. | — | 2025 | → |
| Lacrimal Sac Chronic Lymphocytic Leukemia: A Review of Clinical Features, Investigations, and Management. | Reigler O et al. | — | 2025 | → |
| Leukemia Cutis With Concomitant Seborrheic Keratosis as the Presenting Symptom of Chronic Lymphocytic Leukemia: A Case Report. | Drallmeier M et al. | — | 2025 | → |
| Loss of Heterozygosity in Pediatric Acute Lymphoblastic Leukemia and Its Prognostic Impact: A Retrospective Study. | Styka B et al. | — | 2025 | → |
| Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0. | Solano F et al. | — | 2025 | → |
| NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL. | Ehrmann AS et al. | — | 2025 | → |
| Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study. | Lee CY et al. | — | 2025 | → |
| Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. | Davids MS et al. | — | 2025 | → |
| Pilot evaluation of optical genome mapping in chronic lymphocytic leukemia: complementing FISH analysis. | Erdem S et al. | — | 2025 | → |
| Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future. | McKeague S et al. | — | 2025 | → |
| Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USA. | Bruno DS et al. | — | 2025 | → |
| Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL. | Allan JN et al. | — | 2025 | → |
| Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia. | Lim YJ et al. | — | 2025 | → |
| Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations. | Kim J et al. | — | 2025 | → |
| SOHO State of the Art Updates and Next Questions | Impact of Biologic Markers on Outcomes With Novel Therapy in Chronic Lymphocytic Leukaemia. | Varghese AM et al. | — | 2025 | → |
| SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor. | García-Muñoz R et al. | — | 2025 | → |
| Targeting the p53/xCT/GSH Axis with PRIMA-1<sup>Met</sup> Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia. | Pasino M et al. | — | 2025 | → |
| The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity. | Perez-Castro A et al. | — | 2025 | → |
| The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia. | Seyithanoglu D et al. | — | 2025 | → |
| The Heterogeneity of 13q Deletions in Chronic Lymphocytic Leukemia: Diagnostic Challenges and Clinical Implications. | Xia C et al. | — | 2025 | → |
| The importance of <i>TP53</i> status in cancer therapy: The example of chronic lymphocytic leukemia. | Mirgayazova R et al. | — | 2025 | → |
| The Prevalence of Cytogenetic Abnormalities Detected by Interphase FISH Method in Chronic Lymphocytic Leukemia. | Azhdari S et al. | — | 2025 | → |
| The TP53 tumor suppressor gene: From molecular biology to clinical investigations. | Baliakas P et al. | — | 2025 | → |
| Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. | Jain N et al. | — | 2024 | → |
| Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them. | Borogovac A et al. | — | 2024 | → |
| A genetic profiling guideline to support diagnosis and clinical management of lymphomas. | Sánchez-Beato M et al. | — | 2024 | → |
| An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. | Kittai AS et al. | — | 2024 | → |
| An overview of prognostic markers in patients with CLL. | Braish J et al. | — | 2024 | → |
| Association of Genetic Variants at the <i>CDKN1B</i> and <i>CCND2</i> Loci Encoding p27<i><sup>Kip1</sup></i> and Cyclin D2 Cell Cycle Regulators with Susceptibility and Clinical Course of Chronic Lymphocytic Leukemia. | Ciszak L et al. | — | 2024 | → |
| Association of Genomic Alterations with the Presence of Serum Monoclonal Proteins in Chronic Lymphocytic Leukemia. | Piñeyroa JA et al. | — | 2024 | → |
| BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance. | Robak T et al. | — | 2024 | → |
| CD4+ chronic lymphocytic leukemia in an 86-year-old male veteran: A case report. | Abdelrahim S et al. | — | 2024 | → |
| Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course. | Angotzi F et al. | — | 2024 | → |
| Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis. | Pérez Carretero C et al. | — | 2024 | → |
| CLLU1 as an emerging biomarker in chronic lymphoid leukemia. | Rong C et al. | — | 2024 | → |
| Complex Karyotype Detection in Chronic Lymphocytic Leukemia: A Comparison of Parallel Cytogenetic Cultures Using TPA and IL2+DSP30 from a Single Center. | Kamaso J et al. | — | 2024 | → |
| Complex karyotypes in hematologic disorders: a 12-year single-center study from Lebanon. | Rammal S et al. | — | 2024 | → |
| Consensus guidelines for the management of treatment-naïve chronic lymphocytic leukaemia in Singapore (2024). | Goh YT et al. | — | 2024 | → |
| CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia. | Ahmed HA et al. | — | 2024 | → |
| Cytokine-induced killer cells: new insights for therapy of hematologic malignancies. | Ghanbari Sevari F et al. | — | 2024 | → |
| ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update. | Malcikova J et al. | — | 2024 | → |
| Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region. | Alshemmari SH et al. | — | 2024 | → |
| First-line therapy for high-risk people with chronic lymphocytic leukemia: a network meta-analysis. | Miyamoto K et al. | — | 2024 | → |
| From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy. | Ahmadi SE et al. | — | 2024 | → |
| Frontline Therapy of CLL-Changing Treatment Paradigms. | Coombs CC | — | 2024 | → |
| Gene Mutations Associated With Chronic Lymphocytic Leukemia (CLL) Among Saudi CLL Patients and Treatment Outcomes: A Single-Center Experience. | Alsayari MA et al. | — | 2024 | → |
| Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms - a practical guide to WHO HAEM5. | Tausch E et al. | — | 2024 | → |
| Genomic structural variants analysis in leukemia by a novel cytogenetic technique: Optical genome mapping. | Lu S et al. | — | 2024 | → |
| HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia. | Tizu M et al. | — | 2024 | → |
| Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort. | Martino EA et al. | — | 2024 | → |
| Interleukin-6 And Interleukin-10 Polymorphisms In Chronic Lymphoid Leukemia Patients. | Yildiz S et al. | — | 2024 | → |
| Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation. | Kutsch N et al. | — | 2024 | → |
| Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation. | László T et al. | — | 2024 | → |
| Maintenance therapy for chronic lymphocytic leukaemia. | Lee CH et al. | — | 2024 | → |
| Masked Conditional Variational Autoencoders for Chromosome Straightening. | Li J et al. | — | 2024 | → |
| MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study. | Nano E et al. | — | 2024 | → |
| Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). | Sekar A et al. | — | 2024 | → |
| Noncoding RNAs in B cell non-Hodgkins lymphoma. | Abedi Kichi Z et al. | — | 2024 | → |
| Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia. | Kumar J et al. | — | 2024 | → |
| Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications. | Shabani M et al. | — | 2024 | → |
| Potential New Therapies "ROS-Based" in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis. | Sciaccotta R et al. | — | 2024 | → |
| Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia. | Alshemmari SH et al. | — | 2024 | → |
| Prognostication in chronic lymphocytic leukemia. | Moia R et al. | — | 2024 | → |
| Prognostic Markers in the Era of Targeted Therapies. | Kang S et al. | — | 2024 | → |
| Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities. | Stamatopoulos K et al. | — | 2024 | → |
| Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial. | Eichhorst B et al. | — | 2024 | → |
| Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia. | Patton JT et al. | — | 2024 | → |
| Targeting the DNA damage response in hematological malignancies. | De Mel S et al. | — | 2024 | → |
| The dark side of stemness - the role of hematopoietic stem cells in development of blood malignancies. | Filipek-Gorzała J et al. | — | 2024 | → |
| The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. | Zhang R et al. | — | 2024 | → |
| The molecular map of CLL and Richter's syndrome. | Sud A et al. | — | 2024 | → |
| The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review. | Witkowska M et al. | — | 2024 | → |
| Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. | Al-Sawaf O et al. | — | 2024 | → |
| Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels. | Kismali G et al. | — | 2024 | → |
| Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US. | Yang X et al. | — | 2024 | → |
| Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed. | Fresa A et al. | — | 2024 | → |
| Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT). | Galieni P et al. | — | 2024 | → |
| Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single-cell RNA sequencing. | Kurucova T et al. | — | 2024 | → |
| Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations. | Wiedmeier-Nutor JE et al. | — | 2024 | → |
| What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study. | D'Arena G et al. | — | 2024 | → |
| Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. | Wallace DS et al. | — | 2023 | → |
| A CAPTIVATEing Analysis for Higher-Risk CLL. | Rogers KA | — | 2023 | → |
| A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation. | Miki K et al. | — | 2023 | → |
| Aging and Age-Related Epigenetic Drift in the Pathogenesis of Leukemia and Lymphomas: New Therapeutic Targets. | Allegra A et al. | — | 2023 | → |
| An Extremely Rare Case of Prostate and Bladder Wall Involvement of Chronic Lymphocytic Leukemia. | Thomas M et al. | — | 2023 | → |
| A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting. | Bossi LE et al. | — | 2023 | → |
| CCL3 as Possible Negative Prognostic Factor in Chronic Lymphocytic Leukemia. | Popek-Marciniec S et al. | — | 2023 | → |
| Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies. | Song Y et al. | — | 2023 | → |
| Chronic lymphocytic leukaemia Australasian consensus practice statement. | Anderson MA et al. | — | 2023 | → |
| Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. | Sander B et al. | — | 2023 | → |
| Chronic Lymphocytic Leukemia With Two B-Cell Populations of Discordant Light Chain Restrictions in Individual Patients: Parallel Development of Biclonal B-Cell Neoplasms or Clonal Evolution With Isotype Switch? | Zhao Y et al. | — | 2023 | → |
| Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade. | Yang J et al. | — | 2023 | → |
| Copy Number Variations and Gene Mutations Identified by Multiplex Ligation-Dependent Probe Amplification in Romanian Chronic Lymphocytic Leukemia Patients. | Balla B et al. | — | 2023 | → |
| Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations. | Slot M et al. | — | 2023 | → |
| COX-2/PGE2 upregulation contributes to the chromosome 17p-deleted lymphoma. | Qi L et al. | — | 2023 | → |
| Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). | Nguyen-Khac F et al. | — | 2023 | → |
| Cytogenomics of B-cell non-Hodgkin lymphomas: The "old" meets the "new". | Grau M et al. | — | 2023 | → |
| Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. | Shadman M | — | 2023 | → |
| Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. | Griffin R et al. | — | 2023 | → |
| Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. | Mansouri L et al. | — | 2023 | → |
| Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis. | Nguyen TT et al. | — | 2023 | → |
| Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. | Zhao A et al. | — | 2023 | → |
| Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study. | Qin K et al. | — | 2023 | → |
| Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA. | Coccaro N et al. | — | 2023 | → |
| FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia? | Rhodes J | — | 2023 | → |
| Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL. | Couillez G et al. | — | 2023 | → |
| Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non-specific hypersensitivity reactions. | Abbott J et al. | — | 2023 | → |
| Functional analysis of structural variants in single cells using Strand-seq. | Jeong H et al. | — | 2023 | → |
| Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy. | Morabito F et al. | — | 2023 | → |
| Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of <i>MYD88</i> Mutations. | Ahn A et al. | — | 2023 | → |
| Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. | Johnson PC et al. | — | 2023 | → |
| High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. | Fürstenau M et al. | — | 2023 | → |
| High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. | Mauro FR et al. | — | 2023 | → |
| High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL. | Hengeveld PJ et al. | — | 2023 | → |
| Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. | Hillmen P et al. | — | 2023 | → |
| "Immuno-FlowFISH": Applications for Chronic Lymphocytic Leukemia. | Hui HYL et al. | — | 2023 | → |
| <i>NOTCH1</i>-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential. | Silva Barcelos EC et al. | — | 2023 | → |
| Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax. | Kotmayer L et al. | — | 2023 | → |
| Machine learning and multi-omics data in chronic lymphocytic leukemia: the future of precision medicine? | Tsagiopoulou M et al. | — | 2023 | → |
| Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia. | Witkowska M et al. | — | 2023 | → |
| Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders. | Güell N et al. | — | 2023 | → |
| Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials. | Rizzuto A et al. | — | 2023 | → |
| Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. | Ecker V et al. | — | 2023 | → |
| Noncoding RNA mutations in cancer. | Zhou H et al. | — | 2023 | → |
| Novel precision medicine approaches and treatment strategies in hematological malignancies. | Rosenquist R et al. | — | 2023 | → |
| Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia. | Valkama A et al. | — | 2023 | → |
| Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center. | Linn SM et al. | — | 2023 | → |
| Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico. | Ortiz-Ortiz KJ et al. | — | 2023 | → |
| Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia. | Wan Mohamad Zamri WN et al. | — | 2023 | → |
| Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. | Mollstedt J et al. | — | 2023 | → |
| Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia. | Hoffmann J et al. | — | 2023 | → |
| Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia. | Chocholska S et al. | — | 2023 | → |
| Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic Leukemia. | Lampson BL et al. | — | 2023 | → |
| Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study. | Moldovianu AM et al. | — | 2023 | → |
| Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. | Oder B et al. | — | 2023 | → |
| Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results. | Avenarius MR et al. | — | 2023 | → |
| Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). | Odetola O et al. | — | 2023 | → |
| Role of microRNAs in Chronic Lymphocytic Leukemia. | Autore F et al. | — | 2023 | → |
| Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: A high-resolution population-based study. | Delapierre B et al. | — | 2023 | → |
| Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence? | Chung C et al. | — | 2023 | → |
| Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. | Lee P et al. | — | 2023 | → |
| Targeting BCL2 pathways in CLL: a story of resistance and ingenuity. | Reyes A et al. | — | 2023 | → |
| The Broad Spectrum of <i>TP53</i> Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots. | Lazarian G et al. | — | 2023 | → |
| The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia. | Nagler A et al. | — | 2023 | → |
| The Ultraviolet Irradiation of Keratinocytes Induces Ectopic Expression of LINE-1 Retrotransposon Machinery and Leads to Cellular Senescence. | Touma F et al. | — | 2023 | → |
| Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. | Bantilan KS et al. | — | 2023 | → |
| Toward Cytogenomics: Technical Assessment of Long-Read Nanopore Whole-Genome Sequencing for Detecting Large Chromosomal Alterations in Mantle Cell Lymphoma. | Hansen MH et al. | — | 2023 | → |
| Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. | Al-Sawaf O et al. | — | 2023 | → |
| Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06). | Kim JS et al. | — | 2023 | → |
| Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades. | Alabrach Y et al. | — | 2023 | → |
| Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. | Egyed M et al. | — | 2022 | → |
| A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib. | Mato AR et al. | — | 2022 | → |
| A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. | Abrisqueta P et al. | — | 2022 | → |
| A large fraction of trisomy 12, 17p<sup>-</sup>, and 11q<sup>-</sup> CLL cases carry unidentified microdeletions of <i>miR-15a/16-1</i>. | Pepe F et al. | — | 2022 | → |
| Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment. | Xu X et al. | — | 2022 | → |
| Application of precision medicine in clinical routine in haematology-Challenges and opportunities. | Wästerlid T et al. | — | 2022 | → |
| ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours. | Rio-Machin A | — | 2022 | → |
| Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. | Forconi F et al. | — | 2022 | → |
| CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia. | Perkins B et al. | — | 2022 | → |
| Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. | Ramos-Campoy S et al. | — | 2022 | → |
| Chronic lymphocytic leukaemia clones are detectable decades before diagnosis. | Vojdeman FJ et al. | — | 2022 | → |
| [Chronic lymphocytic leukemia]. | Gauthier M | — | 2022 | → |
| Chronic lymphocytic leukemia in China. | Gale RP | — | 2022 | → |
| Chronic lymphocytic leukemia treatment algorithm 2022. | Hampel PJ et al. | — | 2022 | → |
| CircRNA-miRNA networks in regulating bone disease. | Huang W et al. | — | 2022 | → |
| [Clinical analysis of 20 cases of small B lymphocyte proliferative disease with t (14;19) (q32;q13)]. | Yang H et al. | — | 2022 | → |
| CLL-IPI applied in Binet A CLL: a nationwide cohort study. | Rotbain EC et al. | — | 2022 | → |
| CLL update 2022: A continuing evolution in care. | Kay NE et al. | — | 2022 | → |
| Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation. | Bracher S et al. | — | 2022 | → |
| Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. | Zapatka M et al. | — | 2022 | → |
| Consequences of genetic variants in miRNA genes. | Machowska M et al. | — | 2022 | → |
| Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. | Baliakas P et al. | — | 2022 | → |
| Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. | Raa DGT et al. | — | 2022 | → |
| Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia. | Gasic V et al. | — | 2022 | → |
| Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. | Kharfan-Dabaja MA et al. | — | 2022 | → |
| Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. | Bruch PM et al. | — | 2022 | → |
| Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of <i>MYC</i> Aberrations. | Ondroušková E et al. | — | 2022 | → |
| Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis. | Yu TY et al. | — | 2022 | → |
| Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. | Herishanu Y et al. | — | 2022 | → |
| Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes. | Olbertova H et al. | — | 2022 | → |
| Explainable machine learning for chronic lymphocytic leukemia treatment prediction using only inexpensive tests. | Meiseles A et al. | — | 2022 | → |
| Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia. | Wu Z et al. | — | 2022 | → |
| Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. | Kater AP et al. | — | 2022 | → |
| Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages. | Suárez-Cabrera A et al. | — | 2022 | → |
| Genomic profiling for clinical decision making in lymphoid neoplasms. | de Leval L et al. | — | 2022 | → |
| High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. | Chiodin G et al. | — | 2022 | → |
| Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait? | Brieghel C et al. | — | 2022 | → |
| Increased serum level of alpha-2 macroglobulin and its production by B-lymphocytes in chronic lymphocytic leukemia. | Michelis R et al. | — | 2022 | → |
| Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling. | Batzilla A et al. | — | 2022 | → |
| Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations. | Grenda A et al. | — | 2022 | → |
| In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia. | Alsagaby SA et al. | — | 2022 | → |
| Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. | Bloehdorn J et al. | — | 2022 | → |
| InterTADs: integration of multi-omics data on topologically associated domains, application to chronic lymphocytic leukemia. | Tsagiopoulou M et al. | — | 2022 | → |
| <i>TP53</i> co-mutations as an independent prognostic factor in 2nd and further line therapy-<i>EGFR</i> mutated non-small cell lung cancer IV patients treated with osimertinib. | Roeper J et al. | — | 2022 | → |
| <i>TP53</i> Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia. | Alkhatabi H et al. | — | 2022 | → |
| Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. | Jelloul FZ et al. | — | 2022 | → |
| Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia <i>via</i> Data Mining Mutation Databases. | Soussi T et al. | — | 2022 | → |
| Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. | Chiang CL et al. | — | 2022 | → |
| Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia. | Hanna KS et al. | — | 2022 | → |
| Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia. | Pfister V et al. | — | 2022 | → |
| <i>TP53</i> Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. | Ramos-Campoy S et al. | — | 2022 | → |
| Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. | Rivera D et al. | — | 2022 | → |
| MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. | Matis S et al. | — | 2022 | → |
| Molecular Diagnostic Testing for Hematopoietic Neoplasms: Linking Pathogenic Drivers to Personalized Diagnosis. | Hergott CB et al. | — | 2022 | → |
| Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. | Cramer P et al. | — | 2022 | → |
| Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. | Huber H et al. | — | 2022 | → |
| Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia. | Bagnara D et al. | — | 2022 | → |
| Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). | Puiggros A et al. | — | 2022 | → |
| Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. | Herbst SA et al. | — | 2022 | → |
| Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. | Huang Q et al. | — | 2022 | → |
| SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. | Mellinghoff SC et al. | — | 2022 | → |
| Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. | Piñeyroa JA et al. | — | 2022 | → |
| Small Non-Coding RNAs in Leukemia. | Balatti V et al. | — | 2022 | → |
| Super-Enhancer-Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients. | Liang X et al. | — | 2022 | → |
| The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. | Langerbeins P et al. | — | 2022 | → |
| The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). | Nguyen-Khac F et al. | — | 2022 | → |
| The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. | Visentin A et al. | — | 2022 | → |
| The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study. | De Luca G et al. | — | 2022 | → |
| Towards precision medicine in lymphoid malignancies. | Bühler MM et al. | — | 2022 | → |
| Unusual complications in the management of chronic lymphocytic leukemia. | Gordon MJ et al. | — | 2022 | → |
| Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. | Burger JA et al. | — | 2022 | → |
| Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. | Barr PM et al. | — | 2022 | → |
| Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. | St-Pierre F et al. | — | 2022 | → |
| Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement. | Karbhari N et al. | — | 2022 | → |
| 13q14 Deletion and Its Effect on Prognosis of Chronic Lymphocytic Leukemia. | Khalid K et al. | — | 2021 | → |
| Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective. | Sood N et al. | — | 2021 | → |
| Acalabrutinib in treatment-naive chronic lymphocytic leukemia. | Byrd JC et al. | — | 2021 | → |
| A Case of COVID-19-Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated? | Safarpour D et al. | — | 2021 | → |
| AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression. | Oppezzo P et al. | — | 2021 | → |
| Alterations in The Plasma Expression of mir-15b, mir-195 and the Tumor-Suppressor Gene DLEU7 in Patients with B-Cell Chronic Lymphocytic Leukemia. | Bagheri M et al. | — | 2021 | → |
| An Anomaly with Potential as a New Prognostic Marker in CLL with del(13q): Gain of 16p13.3. | Isik S et al. | — | 2021 | → |
| Antitumor Effects of PRIMA-1 and PRIMA-1<sup>Met</sup> (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? | Menichini P et al. | — | 2021 | → |
| An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. | Salvaris R et al. | — | 2021 | → |
| A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia. | Chauzeix J et al. | — | 2021 | → |
| BH3 Mimetics in Hematologic Malignancies. | Klener P et al. | — | 2021 | → |
| Biclonal evolution of chronic lymphocytic leukaemia. | Zhao Y et al. | — | 2021 | → |
| Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. | Quijada-Álamo M et al. | — | 2021 | → |
| BIRC3 and BIRC5: multi-faceted inhibitors in cancer. | Frazzi R | — | 2021 | → |
| Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. | Bosch F et al. | — | 2021 | → |
| Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking? | Smolej L et al. | — | 2021 | → |
| Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability. | Zavacka K et al. | — | 2021 | → |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Eichhorst B et al. | — | 2021 | → |
| Chronic Lymphocytic Leukemia. | Chiorazzi N et al. | — | 2021 | → |
| Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. | Hallek M et al. | — | 2021 | → |
| Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib. | Brieghel C et al. | — | 2021 | → |
| Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. | Kwok M et al. | — | 2021 | → |
| Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. | Morabito F et al. | — | 2021 | → |
| Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia. | Kolijn PM et al. | — | 2021 | → |
| Current Treatment Options in CLL. | Bewarder M et al. | — | 2021 | → |
| Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal-Results from a population-based cancer registry cohort study. | Cardoso Borges F et al. | — | 2021 | → |
| Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia. | Quijada-Álamo M et al. | — | 2021 | → |
| [Distinguish immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Chinese patients with chronic lymphocytic leukemia]. | Li H et al. | — | 2021 | → |
| Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features. | Soliman DS et al. | — | 2021 | → |
| Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. | Herishanu Y et al. | — | 2021 | → |
| Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. | Ramaiah MJ et al. | — | 2021 | → |
| Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia. | Barrow TM et al. | — | 2021 | → |
| ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both? | Féral K et al. | — | 2021 | → |
| Evaluation of MLPA as a comprehensive molecular cytogenetic tool to detect cytogenetic markers of chronic lymphocytic leukemia in Egyptian patients. | Eid OM et al. | — | 2021 | → |
| Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario. | Seung SJ et al. | — | 2021 | → |
| Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia. | Aguilar-Hernandez MM et al. | — | 2021 | → |
| From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. | González-Gascón-Y-Marín I et al. | — | 2021 | → |
| From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques. | Balla B et al. | — | 2021 | → |
| Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. | Lin WY et al. | — | 2021 | → |
| Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. | Leeksma AC et al. | — | 2021 | → |
| Genomics of Resistance to Targeted Therapies. | Thangavadivel S et al. | — | 2021 | → |
| How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen. | Cabeçadas J et al. | — | 2021 | → |
| Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. | Schetelig J et al. | — | 2021 | → |
| Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways. | Taus P et al. | — | 2021 | → |
| Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. | Jiménez I et al. | — | 2021 | → |
| Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. | Balakrishna J et al. | — | 2021 | → |
| Liquid biopsy technologies for hematological diseases. | Fu Y et al. | — | 2021 | → |
| Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia. | Ciardullo C et al. | — | 2021 | → |
| Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options. | Malcikova J et al. | — | 2021 | → |
| Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. | Smolej L et al. | — | 2021 | → |
| Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia. | Maciel NIG et al. | — | 2021 | → |
| Low prevalence and independent prognostic role of del(11q) in Chinese patients with chronic lymphocytic leukemia. | Zou YX et al. | — | 2021 | → |
| Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. | Wang XV et al. | — | 2021 | → |
| MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia. | Katsaraki K et al. | — | 2021 | → |
| miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. | Sewastianik T et al. | — | 2021 | → |
| Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. | Yi JH et al. | — | 2021 | → |
| Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. | Moia R et al. | — | 2021 | → |
| Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies. | Drillis G et al. | — | 2021 | → |
| Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. | Cuesta-Mateos C et al. | — | 2021 | → |
| Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. | Delestre F et al. | — | 2021 | → |
| Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. | Shah A et al. | — | 2021 | → |
| Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3. | Putowski M et al. | — | 2021 | → |
| Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. | Machnicki MM et al. | — | 2021 | → |
| Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. | Vitale C et al. | — | 2021 | → |
| Prognostic and Predictive Implications of Cytogenetics and Genomics. | Ljungström V et al. | — | 2021 | → |
| Prognostic significance of isochromosome 17q in hematologic malignancies. | Koczkodaj D et al. | — | 2021 | → |
| Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. | Heerema NA et al. | — | 2021 | → |
| Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. | Walker JS et al. | — | 2021 | → |
| Screening and monitoring of the BTK<sup>C481S</sup> mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. | Bödör C et al. | — | 2021 | → |
| Screening for alternative splicing of lncRNA Dleu2 in the mouse liver cell line AML-12. | Kay MK et al. | — | 2021 | → |
| Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. | Benkova K et al. | — | 2021 | → |
| Targeting Bruton's Tyrosine Kinase in CLL. | Ahn IE et al. | — | 2021 | → |
| Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. | Kwok M et al. | — | 2021 | → |
| The Difficult-to-Treat del 17 p Patient-A Case Report in Chronic Lymphocytic Leukemia. | Moldovianu AM et al. | — | 2021 | → |
| The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. | Pérez-Carretero C et al. | — | 2021 | → |
| The future of laboratory testing in chronic lymphocytic leukaemia. | Hotinski AK et al. | — | 2021 | → |
| The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. | Kittai AS et al. | — | 2021 | → |
| The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. | Miazek-Zapala N et al. | — | 2021 | → |
| The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond. | Ding W | — | 2021 | → |
| Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. | Stefaniuk P et al. | — | 2021 | → |
| The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. | Albiol N et al. | — | 2021 | → |
| Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. | van der Straten L et al. | — | 2021 | → |
| Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. | Choi Y et al. | — | 2021 | → |
| Understanding CLL biology through mouse models of human genetics. | Ten Hacken E et al. | — | 2021 | → |
| Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion? | Durak Aras B et al. | — | 2021 | → |
| Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion | Tam CS et al. | — | 2021 | → |
| Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. | Byrd JC et al. | — | 2020 | → |
| A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. | Cohen JA et al. | — | 2020 | → |
| A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia. | Lee CH et al. | — | 2020 | → |
| An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. | Cohen JA et al. | — | 2020 | → |
| A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. | Gordon MJ et al. | — | 2020 | → |
| BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. | Klanova M et al. | — | 2020 | → |
| Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. | Lejeune M et al. | — | 2020 | → |
| BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. | Rogers A et al. | — | 2020 | → |
| Chemoimmunotherapy practice patterns in older patients with chronic lymphocytic leukemia: Impact of age and baseline characteristics on treatment choices. | Jacobsen AM et al. | — | 2020 | → |
| Chemotherapy-free frontline therapy for CLL: is it worth it? | Rhodes JM et al. | — | 2020 | → |
| Choosing The Right Animal Model for Renal Cancer Research. | Sobczuk P et al. | — | 2020 | → |
| Chromatin network markers of leukemia. | Malod-Dognin N et al. | — | 2020 | → |
| [Chromosomal aberrations detection in chronic lymphocytic leukemia by conventional cytogenetics using DSP30 and IL-2]. | Liu HF et al. | — | 2020 | → |
| Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. | Milne K et al. | — | 2020 | → |
| Chronic Lymphocytic Leukemia. | Vaisitti T et al. | — | 2020 | → |
| Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. | Delgado J et al. | — | 2020 | → |
| Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation. | Santoro A et al. | — | 2020 | → |
| Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review. | Grywalska E et al. | — | 2020 | → |
| Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. | Pérez-Carretero C et al. | — | 2020 | → |
| Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. | Liu YC et al. | — | 2020 | → |
| Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. | Williams AM et al. | — | 2020 | → |
| CovCopCan: An efficient tool to detect Copy Number Variation from amplicon sequencing data in inherited diseases and cancer. | Derouault P et al. | — | 2020 | → |
| CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. | Quijada-Álamo M et al. | — | 2020 | → |
| Cytogenetics in the genomic era. | Granada I et al. | — | 2020 | → |
| DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia. | Szoltysek K et al. | — | 2020 | → |
| Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). | Quinquenel A et al. | — | 2020 | → |
| DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. | Yosifov DY et al. | — | 2020 | → |
| Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia? | Gribben JG | — | 2020 | → |
| Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression. | Gonzalez-Rodriguez AP et al. | — | 2020 | → |
| Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. | Herling CD et al. | — | 2020 | → |
| Educational Case: Small Lymphocytic Lymphoma: Diagnostic Features and Prognosis. | Fenu EM et al. | — | 2020 | → |
| Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. | Puła B et al. | — | 2020 | → |
| Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. | Ostasov P et al. | — | 2020 | → |
| Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. | Herishanu Y et al. | — | 2020 | → |
| Genetics of "high-risk" chronic lymphocytic leukemia in the times of chemoimmunotherapy. | Ring A et al. | — | 2020 | → |
| Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression. | Srinivasan VK et al. | — | 2020 | → |
| Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. | Nadeu F et al. | — | 2020 | → |
| Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia. | Chin-Yee B et al. | — | 2020 | → |
| Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance. | Condoluci A et al. | — | 2020 | → |
| Heterogeneity of <i>TP53</i> Mutations and P53 Protein Residual Function in Cancer: Does It Matter? | Monti P et al. | — | 2020 | → |
| Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay. | Farren TW et al. | — | 2020 | → |
| Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. | Byrd JC et al. | — | 2020 | → |
| Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. | Bailey NG et al. | — | 2020 | → |
| Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. | Dubois N et al. | — | 2020 | → |
| LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. | Liu W et al. | — | 2020 | → |
| Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. | Augé H et al. | — | 2020 | → |
| MicroRNA dysregulation and multi-targeted therapy for cancer treatment. | Balatti V et al. | — | 2020 | → |
| MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells. | Bottardi S et al. | — | 2020 | → |
| Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. | Corbingi A et al. | — | 2020 | → |
| Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations. | Zalcberg I et al. | — | 2020 | → |
| Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. | Iovino L et al. | — | 2020 | → |
| Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions. | Buhagiar A et al. | — | 2020 | → |
| Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. | Kikushige Y | — | 2020 | → |
| Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. | Kikushige Y | — | 2020 | → |
| Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. | Gribben JG | — | 2020 | → |
| Precision Medicine Management of Chronic Lymphocytic Leukemia. | Moia R et al. | — | 2020 | → |
| Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. | Stranska K et al. | — | 2020 | → |
| Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball? | González-Gascón-Y-Marín I et al. | — | 2020 | → |
| Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. | Tausch E et al. | — | 2020 | → |
| Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia. | Lee J et al. | — | 2020 | → |
| Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. | Tausch E et al. | — | 2020 | → |
| Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). | Jaramillo S et al. | — | 2020 | → |
| Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. | Kreuzberger N et al. | — | 2020 | → |
| Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia. | Yokus O et al. | — | 2020 | → |
| Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. | Mato AR et al. | — | 2020 | → |
| Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. | Yun X et al. | — | 2020 | → |
| Relationship between Chromosomal Aberrations and Gene Expressions in the p53 Pathway in Chronic Lymphocytic Leukemia. | Öztan G et al. | — | 2020 | → |
| Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. | Scheffold A et al. | — | 2020 | → |
| Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. | Pepe F et al. | — | 2020 | → |
| SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia. | Condoluci A et al. | — | 2020 | → |
| Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017. | Weide R et al. | — | 2020 | → |
| Targeting p53 in chronic lymphocytic leukemia. | Moia R et al. | — | 2020 | → |
| The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. | Jondreville L et al. | — | 2020 | → |
| The functions and properties of cullin-5, a potential therapeutic target for cancers. | Gao F et al. | — | 2020 | → |
| The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. | Kreuzer KA et al. | — | 2020 | → |
| The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. | Brieghel C et al. | — | 2020 | → |
| Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. | Monti P et al. | — | 2020 | → |
| TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. | Roeper J et al. | — | 2020 | → |
| TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. | Morabito F et al. | — | 2020 | → |
| Treatment of Chronic Lymphocytic Leukemia. | Burger JA | — | 2020 | → |
| Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12. | Hoofd C et al. | — | 2020 | → |
| Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia. | Hanna KS | — | 2020 | → |
| US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. | Kim MS et al. | — | 2020 | → |
| Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. | Kater AP et al. | — | 2020 | → |
| Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target. | Hobeika C et al. | — | 2020 | → |
| 1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia. | Daniele G et al. | — | 2019 | → |
| Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. | Awan FT et al. | — | 2019 | → |
| Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia. | Zaprazna K et al. | — | 2019 | → |
| AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival. | Cosimo E et al. | — | 2019 | → |
| A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. | Yin S et al. | — | 2019 | → |
| Analysis of basal chromosome instability in patients with chronic lymphocytic leukaemia. | Palmitelli M et al. | — | 2019 | → |
| Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. | Hu B et al. | — | 2019 | → |
| A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia. | Mosquera Orgueira A et al. | — | 2019 | → |
| BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. | Schleiss C et al. | — | 2019 | → |
| Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. | Raponi S et al. | — | 2019 | → |
| Chronic lymphocytic leukaemia: from genetics to treatment. | Bosch F et al. | — | 2019 | → |
| Chronic lymphocytic leukemia with deletion 17p: An Indian scenario. | Gogia A et al. | — | 2019 | → |
| Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. | Emond B et al. | — | 2019 | → |
| Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years. | Kruzova L et al. | — | 2019 | → |
| Computational Methods for Detection of Differentially Methylated Regions Using Kernel Distance and Scan Statistics. | Dunbar F et al. | — | 2019 | → |
| Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. | Ziegler CGK et al. | — | 2019 | → |
| Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. | Harkins RA et al. | — | 2019 | → |
| Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia. | Miller CR et al. | — | 2019 | → |
| Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. | Baliakas P et al. | — | 2019 | → |
| Cytogenetic landscape in 1012 newly diagnosed chronic lymphocytic leukemia. | Senouci A et al. | — | 2019 | → |
| Deep targeted sequencing of <i>TP53</i> in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment. | Brieghel C et al. | — | 2019 | → |
| Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia. | Li X et al. | — | 2019 | → |
| Detection of Differentially Methylated Regions Using Bayes Factor for Ordinal Group Responses. | Dunbar F et al. | — | 2019 | → |
| Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. | Giacopelli B et al. | — | 2019 | → |
| Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. | Moysiadis T et al. | — | 2019 | → |
| Dissecting CLL through high-dimensional single-cell technologies. | Gohil SH et al. | — | 2019 | → |
| Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia. | Huang YJ et al. | — | 2019 | → |
| Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. | Wang J et al. | — | 2019 | → |
| Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. | Veneziano D et al. | — | 2019 | → |
| Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study). | Szász R et al. | — | 2019 | → |
| Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. | Autore F et al. | — | 2019 | → |
| Emerging treatment options for patients with p53-pathway-deficient CLL. | Aitken MJL et al. | — | 2019 | → |
| Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. | Soumerai JD et al. | — | 2019 | → |
| Examination of clonal evolution in chronic lymphocytic leukemia. | Koczkodaj D et al. | — | 2019 | → |
| Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. | Zaborsky N et al. | — | 2019 | → |
| Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status. | Shea LK et al. | — | 2019 | → |
| Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. | Munir T et al. | — | 2019 | → |
| First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. | Sylvan SE et al. | — | 2019 | → |
| From Biology to Therapy: The CLL Success Story. | Yosifov DY et al. | — | 2019 | → |
| Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. | Kostopoulou F et al. | — | 2019 | → |
| Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. | Ramassone A et al. | — | 2019 | → |
| Genomics-Enabled Precision Medicine for Cancer. | Roos A et al. | — | 2019 | → |
| Growth dynamics in naturally progressing chronic lymphocytic leukaemia. | Gruber M et al. | — | 2019 | → |
| How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. | Yeung CCS et al. | — | 2019 | → |
| Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. | Montillo M et al. | — | 2019 | → |
| IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. | Fang H et al. | — | 2019 | → |
| "Immuno-flowFISH" for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia. | Hui HYL et al. | — | 2019 | → |
| Improved Interpretability of Machine Learning Model Using Unsupervised Clustering: Predicting Time to First Treatment in Chronic Lymphocytic Leukemia. | Chen D et al. | — | 2019 | → |
| In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. | Severin F et al. | — | 2019 | → |
| Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. | Wang HQ et al. | — | 2019 | → |
| Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. | Wdowiak K et al. | — | 2019 | → |
| Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing. | Zucker MR et al. | — | 2019 | → |
| Investigation of <i>MDM2</i> Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia | Darbaş Ş et al. | — | 2019 | → |
| Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. | Byrd JC et al. | — | 2019 | → |
| Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. | Kipps TJ et al. | — | 2019 | → |
| Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. | Herishanu Y et al. | — | 2019 | → |
| MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. | Cerna K et al. | — | 2019 | → |
| Molecular pathogenesis of chronic lymphocytic leukaemia. | Crassini K et al. | — | 2019 | → |
| Monoclonal B-cell lymphocytosis. | Maitre E et al. | — | 2019 | → |
| MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. | Improgo MR et al. | — | 2019 | → |
| New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data. | Mosquera Orgueira A et al. | — | 2019 | → |
| Noncoding RNA genes in cancer pathogenesis. | Pekarsky Y et al. | — | 2019 | → |
| Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma. | Ryan RJH et al. | — | 2019 | → |
| Overview of non-coding mutations in chronic lymphocytic leukemia. | Spina V et al. | — | 2019 | → |
| PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. | Rhodes JM et al. | — | 2019 | → |
| Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. | Udd KA et al. | — | 2019 | → |
| Precision oncology in Latin America: current situation, challenges and perspectives. | Calderón-Aparicio A et al. | — | 2019 | → |
| Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. | Visentin A et al. | — | 2019 | → |
| Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. | Soumerai JD et al. | — | 2019 | → |
| Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. | Kim HT et al. | — | 2019 | → |
| Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. | Alsagaby SA et al. | — | 2019 | → |
| Purine-Metabolising Enzymes and Apoptosis in Cancer. | Camici M et al. | — | 2019 | → |
| Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis. | Nuttall E et al. | — | 2019 | → |
| Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. | Seymour EK et al. | — | 2019 | → |
| Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. | Andersen NS et al. | — | 2019 | → |
| Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. | Kittai AS et al. | — | 2019 | → |
| Relevance of TP53 for CLL diagnostics. | Catherwood MA et al. | — | 2019 | → |
| Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. | Tschumper RC et al. | — | 2019 | → |
| Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. | Hu B et al. | — | 2019 | → |
| Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. | Jebaraj BMC et al. | — | 2019 | → |
| Significance of the microRNA‑17‑92 gene cluster expressed in B‑cell non‑Hodgkin's lymphoma. | Yan S et al. | — | 2019 | → |
| SLAMF6 in health and disease: Implications for therapeutic targeting. | Yigit B et al. | — | 2019 | → |
| [Survival analysis of 118 chronic lymphocytic leukemia patients with abnormal TP53 gene in the era of traditional immunochemotherapy]. | Li XT et al. | — | 2019 | → |
| Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. | Baliakas P et al. | — | 2019 | → |
| Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. | Yalniz FF et al. | — | 2019 | → |
| Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance. | Pramil E et al. | — | 2019 | → |
| The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution. | Mosquera Orgueira A et al. | — | 2019 | → |
| The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. | Visentin A et al. | — | 2019 | → |
| The evolving treatment landscape of chronic lymphocytic leukemia. | Schiattone L et al. | — | 2019 | → |
| The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma. | Schieber M et al. | — | 2019 | → |
| TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia. | Szymańska A et al. | — | 2019 | → |
| Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness. | Alsagaby SA | — | 2019 | → |
| Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. | Woyach JA | — | 2019 | → |
| Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. | Woyach JA | — | 2019 | → |
| Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. | Degaud M et al. | — | 2019 | → |
| Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. | Fischer K et al. | — | 2019 | → |
| Venetoclax: evidence to date and clinical potential. | Juárez-Salcedo LM et al. | — | 2019 | → |
| A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion. | Miao Y et al. | — | 2018 | → |
| Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity. | Starkova J et al. | — | 2018 | → |
| An algorithmic approach to diagnose haematolymphoid neoplasms in effusion by combining morphology, immunohistochemistry and molecular cytogenetics. | Chen L et al. | — | 2018 | → |
| Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. | Mozas P et al. | — | 2018 | → |
| Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. | Williams AM et al. | — | 2018 | → |
| An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. | Alharthi A et al. | — | 2018 | → |
| Array CGH analysis reveals deletion of chromosome 22q11 in CLL with normal karyotype and no fish alterations. | Mestichelli F et al. | — | 2018 | → |
| A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. | Rogers KA et al. | — | 2018 | → |
| Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. | Sandoval-Sus JD et al. | — | 2018 | → |
| Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. | Mauro FR et al. | — | 2018 | → |
| BCL2 and miR-15/16: from gene discovery to treatment. | Pekarsky Y et al. | — | 2018 | → |
| Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. | Cavallari M et al. | — | 2018 | → |
| CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. | Hay KA et al. | — | 2018 | → |
| CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. | Ting YS et al. | — | 2018 | → |
| CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. | Gooden CE et al. | — | 2018 | → |
| Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia. | Andersen BL et al. | — | 2018 | → |
| Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. | González-Gascón Y Marín I et al. | — | 2018 | → |
| Chronic lymphocytic leukaemia. | Hallek M et al. | — | 2018 | → |
| Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. | Puente XS et al. | — | 2018 | → |
| Chronic Lymphocytic Leukemia: Diagnosis and Treatment. | Strati P et al. | — | 2018 | → |
| Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype? | Kreinitz N et al. | — | 2018 | → |
| Chronic lymphocytic leukemia treatment algorithm 2018. | Parikh SA | — | 2018 | → |
| Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway. | Xia L et al. | — | 2018 | → |
| Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLL. | Klintman J et al. | — | 2018 | → |
| Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. | Takahashi K et al. | — | 2018 | → |
| Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling. | Friedman DR et al. | — | 2018 | → |
| Clinicohematological parameters and outcomes in a cohort of chronic lymphocytic leukemia patients with Deletion 17p from Pakistan. | Mahmood R et al. | — | 2018 | → |
| Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. | Herling CD et al. | — | 2018 | → |
| Cohesin RAD21 Gene Promoter Methylation in Patients with Chronic Lymphocytic Leukemia. | Ioannidou A et al. | — | 2018 | → |
| Combined somatic mutation and copy number analysis in the survival of familial CLL. | Zhou W et al. | — | 2018 | → |
| Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. | Kay NE et al. | — | 2018 | → |
| Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia. | Rogne M et al. | — | 2018 | → |
| Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. | Yi S et al. | — | 2018 | → |
| DNA damage pathways and B-cell lymphomagenesis. | Knittel G et al. | — | 2018 | → |
| DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status. | Grgurevic S et al. | — | 2018 | → |
| "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain. | Chapiro E et al. | — | 2018 | → |
| Drug-perturbation-based stratification of blood cancer. | Dietrich S et al. | — | 2018 | → |
| ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. | Malcikova J et al. | — | 2018 | → |
| Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. | Burger JA et al. | — | 2018 | → |
| Expression of autophagy related genes in chronic lymphocytic leukemia is associated with disease course. | Kong YL et al. | — | 2018 | → |
| Expression of <i>COBLL1</i> encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. | Plešingerová H et al. | — | 2018 | → |
| From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development. | Ghia P | — | 2018 | → |
| Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. | Tissino E et al. | — | 2018 | → |
| GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death. | Alves-Silva JC et al. | — | 2018 | → |
| Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. | Schuh AH et al. | — | 2018 | → |
| Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. | Jakšić B et al. | — | 2018 | → |
| Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. | Agathangelidis A et al. | — | 2018 | → |
| Ibrutinib. | Charalambous A et al. | — | 2018 | → |
| Ibrutinib: coming of age? | Brown JR | — | 2018 | → |
| Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. | Woyach JA et al. | — | 2018 | → |
| Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses. | Vetro C et al. | — | 2018 | → |
| Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia. | Hui H et al. | — | 2018 | → |
| Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. | Abur Ü et al. | — | 2018 | → |
| <i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. | Campo E et al. | — | 2018 | → |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. | Hallek M et al. | — | 2018 | → |
| Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). | Byrd JC et al. | — | 2018 | → |
| Long non-coding RNAs in hematopoietic regulation. | Li W et al. | — | 2018 | → |
| MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. | Amodio N et al. | — | 2018 | → |
| Management of melanoma in patients with chronic lymphocytic leukemia. | Archibald WJ et al. | — | 2018 | → |
| Microarray Expression Profiling of microRNAs Reveals Potential Biomarkers for Hepatocellular Carcinoma. | Zhu HR et al. | — | 2018 | → |
| Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. | Gutjahr JC et al. | — | 2018 | → |
| Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. | Tomuleasa C et al. | — | 2018 | → |
| Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. | Autore F et al. | — | 2018 | → |
| Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O<sub>2-</sub>· production in cancer cells. | Cordani M et al. | — | 2018 | → |
| Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. | Roos-Weil D et al. | — | 2018 | → |
| NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. | Rosati E et al. | — | 2018 | → |
| NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases. | Zou Y et al. | — | 2018 | → |
| Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. | Stilgenbauer S et al. | — | 2018 | → |
| On the architecture of translational research designed to control chronic lymphocytic leukemia. | Hallek M | — | 2018 | → |
| Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3). | Malli T et al. | — | 2018 | → |
| Phenotypic Characterization of Trisomy 12 Monoclonal B-Cell Lymphocytosis. | Sorigue M et al. | — | 2018 | → |
| Pitfalls of Combining Novel Agents in Lymphoma. | Rodgers TD et al. | — | 2018 | → |
| Potential of BCL2 as a target for chronic lymphocytic leukemia treatment. | Moia R et al. | — | 2018 | → |
| Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. | Buccheri V et al. | — | 2018 | → |
| Prognostic Factors in the Era of Targeted Therapies in CLL. | Boddu P et al. | — | 2018 | → |
| Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort study. | Flowers CR et al. | — | 2018 | → |
| Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. | Bordron A et al. | — | 2018 | → |
| Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. | Gosangi B et al. | — | 2018 | → |
| Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. | Appleby N et al. | — | 2018 | → |
| Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. | Robak T et al. | — | 2018 | → |
| Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. | Thompson PA et al. | — | 2018 | → |
| State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. | Mirzaei H et al. | — | 2018 | → |
| Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. | Barr PM et al. | — | 2018 | → |
| Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. | Edwards V DK et al. | — | 2018 | → |
| Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. | Steinbrecher D et al. | — | 2018 | → |
| The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study. | Mescher C et al. | — | 2018 | → |
| The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. | Martínez-Trillos A et al. | — | 2018 | → |
| The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. | Brown JR et al. | — | 2018 | → |
| The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. | Peterson JF et al. | — | 2018 | → |
| Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. | Derenzini E et al. | — | 2018 | → |
| Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. | Rafei H et al. | — | 2018 | → |
| Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. | Agarwal R et al. | — | 2018 | → |
| Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia. | Filiú-Braga LDC et al. | — | 2018 | → |
| Venetoclax: A new wave in hematooncology. | Mihalyova J et al. | — | 2018 | → |
| Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies. | Olin JL et al. | — | 2018 | → |
| Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. | Seymour JF et al. | — | 2018 | → |
| What is the optimal management of older CLL patients? | Woyach JA | — | 2018 | → |
| Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV<sup>mut</sup> and IgHV<sup>unmut</sup> subgroups. | Burns A et al. | — | 2018 | → |
| Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia. | Carvalho Alves-Silva J et al. | — | 2017 | → |
| Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. | Grange B et al. | — | 2017 | → |
| Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. | Shustik C et al. | — | 2017 | → |
| An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. | Rigolin GM et al. | — | 2017 | → |
| A novel canine B-cell leukaemia cell line. Establishment, characterisation and sensitivity to chemotherapeutics. | Pawlak A et al. | — | 2017 | → |
| Antigen receptor stereotypy in chronic lymphocytic leukemia. | Stamatopoulos K et al. | — | 2017 | → |
| Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. | D'Abundo L et al. | — | 2017 | → |
| B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. | Vangapandu HV et al. | — | 2017 | → |
| Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion. | Lozano-Santos C et al. | — | 2017 | → |
| Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia. | Amin NA et al. | — | 2017 | → |
| Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. | Podhorecka M et al. | — | 2017 | → |
| Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. | Laurenti L et al. | — | 2017 | → |
| Chromosomal aberrations detected by Fluorescence in situ hybridization in 344 Brazilian chronic lymphocytic leukemia patients. | Zorovich MESLDM et al. | — | 2017 | → |
| Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients. | Jarosova M et al. | — | 2017 | → |
| Chronic lymphocytic leukaemia. | Kipps TJ et al. | — | 2017 | → |
| Chronic lymphocytic leukaemia genomics and the precision medicine era. | Ghamlouch H et al. | — | 2017 | → |
| Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. | Tees MT et al. | — | 2017 | → |
| Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. | Delgado J et al. | — | 2017 | → |
| Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. | Li H et al. | — | 2017 | → |
| Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. | Collado R et al. | — | 2017 | → |
| Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. | Xochelli A et al. | — | 2017 | → |
| Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. | Lynch RC et al. | — | 2017 | → |
| Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. | Lazarian G et al. | — | 2017 | → |
| Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. | Onaindia A et al. | — | 2017 | → |
| Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. | Chan TS et al. | — | 2017 | → |
| Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada. | Huang SJ et al. | — | 2017 | → |
| Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. | Ahn IE et al. | — | 2017 | → |
| Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. | Purroy N et al. | — | 2017 | → |
| Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report. | Liu G et al. | — | 2017 | → |
| Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. | Van Roosbroeck K et al. | — | 2017 | → |
| Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion. | Bagacean C et al. | — | 2017 | → |
| Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. | Aw A et al. | — | 2017 | → |
| Current Treatment of Chronic Lymphocytic Leukemia. | Jamroziak K et al. | — | 2017 | → |
| Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran. | Rahimi H et al. | — | 2017 | → |
| Development of locus specific sub-clone separation by fluorescence in situ hybridization in suspension in chronic lymphocytic leukemia. | Do CH et al. | — | 2017 | → |
| Diagnosis and classification of hematologic malignancies on the basis of genetics. | Taylor J et al. | — | 2017 | → |
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. | Herndon TM et al. | — | 2017 | → |
| Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications. | Wu SJ et al. | — | 2017 | → |
| Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. | Turtle CJ et al. | — | 2017 | → |
| Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. | Davies NJ et al. | — | 2017 | → |
| Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia. | Dos Santos PC et al. | — | 2017 | → |
| Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. | Ahn IE et al. | — | 2017 | → |
| Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment. | Ghia P et al. | — | 2017 | → |
| Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. | Cutrona G et al. | — | 2017 | → |
| EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. | Young E et al. | — | 2017 | → |
| Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. | Marini BL et al. | — | 2017 | → |
| Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. | Filip AA et al. | — | 2017 | → |
| FCR achieves long-term durable remissions in patients with <i>IGHV</i>-mutated CLL. | Chai-Adisaksopha C et al. | — | 2017 | → |
| Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. | Algrin C et al. | — | 2017 | → |
| Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. | Edelmann J et al. | — | 2017 | → |
| From genome to proteome: Looking beyond DNA and RNA in chronic lymphocytic leukemia. | Thurgood LA et al. | — | 2017 | → |
| Front-line treatment of CLL in the era of novel agents. | Robak T et al. | — | 2017 | → |
| Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. | Cosson A et al. | — | 2017 | → |
| Genetic Heterogeneity in Chronic Lymphocytic Leukemia: What Can Conventional Cytogenetics Add? | Hernández-Rivas JÁ et al. | — | 2017 | → |
| Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. | Rosenquist R et al. | — | 2017 | → |
| Genomic data integration in chronic lymphocytic leukemia. | Fernández-Martínez JL et al. | — | 2017 | → |
| Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. | Robak T et al. | — | 2017 | → |
| Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL. | González-Gascón Y Marín I et al. | — | 2017 | → |
| Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature. | Annalisa A et al. | — | 2017 | → |
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. | Zelenetz AD et al. | — | 2017 | → |
| IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. | Piccaluga PP et al. | — | 2017 | → |
| IGHV mutational status testing in chronic lymphocytic leukemia. | Crombie J et al. | — | 2017 | → |
| Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia. | Villa-Álvarez M et al. | — | 2017 | → |
| <i>MicroRNA</i> dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. | Rassenti LZ et al. | — | 2017 | → |
| Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. | Sutton LA et al. | — | 2017 | → |
| Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. | Freise KJ et al. | — | 2017 | → |
| Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. | Yi S et al. | — | 2017 | → |
| Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. | Fink AM et al. | — | 2017 | → |
| Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. | Murphy EJ et al. | — | 2017 | → |
| Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. | Mátrai Z et al. | — | 2017 | → |
| Long non-coding RNAs in B-cell malignancies: a comprehensive overview. | Nobili L et al. | — | 2017 | → |
| Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. | Le Bris Y et al. | — | 2017 | → |
| Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia. | Kuss BJ et al. | — | 2017 | → |
| Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. | Edelmann J et al. | — | 2017 | → |
| Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of <i>memo</i>. | Egle A | — | 2017 | → |
| MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. | Vargova K et al. | — | 2017 | → |
| Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. | Bittolo T et al. | — | 2017 | → |
| New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. | Tripathi R et al. | — | 2017 | → |
| New Pharmacotherapies in Chronic Lymphocytic Leukemia. | Olin JL et al. | — | 2017 | → |
| New Treatment Paradigms Defined for Chronic Lymphocytic Leukemia. | Moran M et al. | — | 2017 | → |
| Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. | Quijada-Álamo M et al. | — | 2017 | → |
| NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. | Pozzo F et al. | — | 2017 | → |
| Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. | Lachowiez C et al. | — | 2017 | → |
| Optimizing frontline therapy of CLL based on clinical and biological factors. | Fischer K et al. | — | 2017 | → |
| p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. | Tessoulin B et al. | — | 2017 | → |
| Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletions. | Puiggros A et al. | — | 2017 | → |
| Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients. | Liu G et al. | — | 2017 | → |
| Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. | Salem AH et al. | — | 2017 | → |
| Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia. | Rossi D et al. | — | 2017 | → |
| Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. | Huber H et al. | — | 2017 | → |
| Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. | D'Arena G et al. | — | 2017 | → |
| Rare germline variants in ATM are associated with chronic lymphocytic leukemia. | Tiao G et al. | — | 2017 | → |
| Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. | Ma ES | — | 2017 | → |
| Regulation of Autophagy by MiRNAs and Their Emerging Roles in Tumorigenesis and Cancer Treatment. | Chen L et al. | — | 2017 | → |
| Regulatory effects of berberine on microRNome in Cancer and other conditions. | Ayati SH et al. | — | 2017 | → |
| Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. | Strati P et al. | — | 2017 | → |
| Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. | Schetelig J et al. | — | 2017 | → |
| Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China. | Li H et al. | — | 2017 | → |
| Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. | Yu L et al. | — | 2017 | → |
| TAp73 and ΔNp73 relative expression in Egyptian patients with lymphoid neoplasms. | Hamdy MSA et al. | — | 2017 | → |
| Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. | Stamatopoulos B et al. | — | 2017 | → |
| Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. | Arnason JE et al. | — | 2017 | → |
| Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions. | Thomay K et al. | — | 2017 | → |
| The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. | Vojdeman FJ et al. | — | 2017 | → |
| The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. | Stengel A et al. | — | 2017 | → |
| The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. | Sacco A et al. | — | 2017 | → |
| The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. | Miller CR et al. | — | 2017 | → |
| The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. | Gaidano G et al. | — | 2017 | → |
| The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study. | Yi S et al. | — | 2017 | → |
| The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. | Tran PN et al. | — | 2017 | → |
| TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases. | Kulaç İ et al. | — | 2017 | → |
| Trisomy 12 assessment by conventional fluorescence in-situ hybridization (FISH), FISH in suspension (FISH-IS) and laser scanning cytometry (LSC) in chronic lymphocytic leukemia. | Do CH et al. | — | 2017 | → |
| Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. | Knittel G et al. | — | 2017 | → |
| Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. | Rassy EE et al. | — | 2017 | → |
| USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. | Agathanggelou A et al. | — | 2017 | → |
| Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. | Roberts AW et al. | — | 2017 | → |
| What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017? | Voorhies BN et al. | — | 2017 | → |
| What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia? | Cheson BD | — | 2017 | → |
| Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. | Sánchez-Martínez D et al. | — | 2016 | → |
| Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. | Baliakas P et al. | — | 2016 | → |
| Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). | Cramer P et al. | — | 2016 | → |
| A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. | González-Gascón Y Marín I et al. | — | 2016 | → |
| A link between hypercholesterolemia and chronic lymphocytic leukemia. | Chow S et al. | — | 2016 | → |
| Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL). | Kasar S et al. | — | 2016 | → |
| Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53. | Ogasawara MA et al. | — | 2016 | → |
| An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. | International CLL-IPI working group | — | 2016 | → |
| A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. | Gentile M et al. | — | 2016 | → |
| A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia. | Amin NA et al. | — | 2016 | → |
| Association of <i>Bax</i> Expression and <i>Bcl2/Bax</i> Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia. | Vucicevic K et al. | — | 2016 | → |
| ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). | Jiang Y et al. | — | 2016 | → |
| ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. | Kwok M et al. | — | 2016 | → |
| Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. | Janovska P et al. | — | 2016 | → |
| Biomarkers of genome instability and cancer epigenetics. | Reis AH et al. | — | 2016 | → |
| BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients. | Alhourani E et al. | — | 2016 | → |
| Blood disorders stepping into the limelight. | Jäger U et al. | — | 2016 | → |
| Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. | Lamothe B et al. | — | 2016 | → |
| CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. | Dal Bo M et al. | — | 2016 | → |
| Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. | Van Damme M et al. | — | 2016 | → |
| Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? | Brown JR et al. | — | 2016 | → |
| Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. | Rendeiro AF et al. | — | 2016 | → |
| Chronic lymphocytic leukaemia. | Scarfò L et al. | — | 2016 | → |
| Chronic lymphocytic leukemia: a clinical review including Korean cohorts. | Jeon YW et al. | — | 2016 | → |
| Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. | Patten PE et al. | — | 2016 | → |
| Chronic lymphocytic leukemia (CLL)-Then and now. | Rai KR et al. | — | 2016 | → |
| Chronic lymphocytic leukemia: Time to go past genomics? | Roos-Weil D et al. | — | 2016 | → |
| Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. | Rosenquist R et al. | — | 2016 | → |
| Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. | Kharfan-Dabaja MA et al. | — | 2016 | → |
| Clinical significance of microRNAs in chronic and acute human leukemia. | Yeh CH et al. | — | 2016 | → |
| Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib. | Cramer P et al. | — | 2016 | → |
| CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia. | Ciszak L et al. | — | 2016 | → |
| Detection of chromosomal changes in chronic lymphocytic leukemia using classical cytogenetic methods and FISH: application of rich mitogen mixtures for lymphocyte cultures. | Koczkodaj D et al. | — | 2016 | → |
| Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. | Rodrigues CA et al. | — | 2016 | → |
| Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. | Sun R et al. | — | 2016 | → |
| Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations. | Jeromin S et al. | — | 2016 | → |
| Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. | Sutton LA et al. | — | 2016 | → |
| Dogs as a Model for Cancer. | Gardner HL et al. | — | 2016 | → |
| Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia. | Acunzo M et al. | — | 2016 | → |
| Efficacy of DSP30-IL2/TPA for detection of cytogenetic abnormalities in chronic lymphocytic leukaemia/small lymphocytic lymphoma. | Holmes PJ et al. | — | 2016 | → |
| Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders. | Bao Y et al. | — | 2016 | → |
| ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. | Ladetto M et al. | — | 2016 | → |
| Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. | Dartigeas C et al. | — | 2016 | → |
| Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. | Carli G et al. | — | 2016 | → |
| Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. | Bachow SH et al. | — | 2016 | → |
| Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. | Rigolin GM et al. | — | 2016 | → |
| FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. | Dubuc AM et al. | — | 2016 | → |
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. | Thompson PA et al. | — | 2016 | → |
| Gene mutations in chronic lymphocytic leukemia. | Amin NA et al. | — | 2016 | → |
| Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. | Tausch E et al. | — | 2016 | → |
| Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. | Hillmen P et al. | — | 2016 | → |
| Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. | Barrientos JC | — | 2016 | → |
| ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. | Krenn PW et al. | — | 2016 | → |
| Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature. | DE Braekeleer M et al. | — | 2016 | → |
| Immunostimulation by cytosine-phosphate-guanine oligodeoxynucleotides in combination with IL-2 can improve the success rate of karyotype analysis in chronic lymphocytic leukaemia. | Lin X et al. | — | 2016 | → |
| Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. | da Cunha-Bang C et al. | — | 2016 | → |
| Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. | Rogers KA et al. | — | 2016 | → |
| Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease. | Gorniak P et al. | — | 2016 | → |
| Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada. | Huang SJ et al. | — | 2016 | → |
| Initial therapy of chronic lymphocytic leukemia. | Eichhorst B et al. | — | 2016 | → |
| Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? | Pospisilova S et al. | — | 2016 | → |
| Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia-Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears. | Alhourani E et al. | — | 2016 | → |
| Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. | Blanco G et al. | — | 2016 | → |
| lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. | Ronchetti D et al. | — | 2016 | → |
| Long non-coding RNAs in normal and malignant hematopoiesis. | Nobili L et al. | — | 2016 | → |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. | Fischer K et al. | — | 2016 | → |
| Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. | Hayakawa K et al. | — | 2016 | → |
| Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. | Ten Hacken E et al. | — | 2016 | → |
| MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies? | Van Roosbroeck K et al. | — | 2016 | → |
| Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. | Kovacs G et al. | — | 2016 | → |
| MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. | Hernández-Sánchez M et al. | — | 2016 | → |
| Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K). | Grygalewicz B et al. | — | 2016 | → |
| Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. | Machiela MJ et al. | — | 2016 | → |
| MYC rearranged B-cell neoplasms: Impact of genetics on classification. | Haberl S et al. | — | 2016 | → |
| NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. | Mansouri L et al. | — | 2016 | → |
| NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. | Pozzo F et al. | — | 2016 | → |
| Novel mechanisms of regulation of miRNAs in CLL. | Balatti V et al. | — | 2016 | → |
| Practical approach to management of chronic lymphocytic leukemia. | Smolej L et al. | — | 2016 | → |
| Prognostication of chronic lymphocytic leukemia in the era of new agents. | Eichhorst B et al. | — | 2016 | → |
| Prognostic factors and risk stratification in chronic lymphocytic leukemia. | Parikh SA et al. | — | 2016 | → |
| Prognostic Factors for Chronic Lymphocytic Leukemia. | Chen C et al. | — | 2016 | → |
| Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? | Baliakas P et al. | — | 2016 | → |
| Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. | Gentile M et al. | — | 2016 | → |
| Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. | Byrd JC et al. | — | 2016 | → |
| Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. | Mato A et al. | — | 2016 | → |
| Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia. | Oliveira-Santos W et al. | — | 2016 | → |
| Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia. | Langerbeins P et al. | — | 2016 | → |
| Sequencing of chronic lymphocytic leukemia therapies. | Barrientos JC | — | 2016 | → |
| SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients. | Mitsui T et al. | — | 2016 | → |
| Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia. | Sellmann L et al. | — | 2016 | → |
| Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. | Parikh SA et al. | — | 2016 | → |
| Simultaneous existence of acute myeloid leukemia and chronic lymphocytic leukemia: a case report. | Al Mussaed E et al. | — | 2016 | → |
| SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. | Bologna C et al. | — | 2016 | → |
| Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia. | Berquet L et al. | — | 2016 | → |
| State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. | Cramer P et al. | — | 2016 | → |
| Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. | D'Avola A et al. | — | 2016 | → |
| Synergy: karyotypes and mutations in CLL. | Abruzzo LV | — | 2016 | → |
| Targeted Therapy of CLL. | Al-Sawaf O et al. | — | 2016 | → |
| Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism. | Liu J et al. | — | 2016 | → |
| TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. | Bresin A et al. | — | 2016 | → |
| The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. | Molica S et al. | — | 2016 | → |
| The CLL-IPI applied in a population-based cohort. | da Cunha-Bang C et al. | — | 2016 | → |
| The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. | Van Dyke DL et al. | — | 2016 | → |
| The European Hematology Association Roadmap for European Hematology Research: a consensus document. | Engert A et al. | — | 2016 | → |
| The molecular pathogenesis of chronic lymphocytic leukaemia. | Fabbri G et al. | — | 2016 | → |
| The mutational signature of chronic lymphocytic leukemia. | Parker H et al. | — | 2016 | → |
| The parallel application of karyotype interphase and metaphase FISH after DSP-30/IL-2 stimulation is necessary for the investigation of chronic lymphocytic leukemia. | Karakosta M et al. | — | 2016 | → |
| The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia. | Matuszak M et al. | — | 2016 | → |
| The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. | Jacobs RW et al. | — | 2016 | → |
| The t(11;14)(q13;q32)/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia. | Schliemann I et al. | — | 2016 | → |
| To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients. | Piszcz J et al. | — | 2016 | → |
| TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing. | Minervini CF et al. | — | 2016 | → |
| Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. | Pandzic T et al. | — | 2016 | → |
| Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. | Zent CS et al. | — | 2016 | → |
| Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. | Pulte D et al. | — | 2016 | → |
| UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? | Bhoi S et al. | — | 2016 | → |
| Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. | Sattari A et al. | — | 2016 | → |
| Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia. | Wu YJ et al. | — | 2016 | → |
| A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. | Queirós AC et al. | — | 2015 | → |
| Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia. | Truger MS et al. | — | 2015 | → |
| Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. | Poon ML et al. | — | 2015 | → |
| A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. | Hernández JÁ et al. | — | 2015 | → |
| CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. | Martinez-Torres AC et al. | — | 2015 | → |
| Characterization of large structural genetic mosaicism in human autosomes. | Machiela MJ et al. | — | 2015 | → |
| Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. | Rigolin GM et al. | — | 2015 | → |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Eichhorst B et al. | — | 2015 | → |
| Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist. | Pinilla-Ibarz J et al. | — | 2015 | → |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. | Zelenetz AD et al. | — | 2015 | → |
| [Chronic lymphocytic leukemia : treatment concepts in transition]. | Eichhorst B et al. | — | 2015 | → |
| Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients. | Oberic L et al. | — | 2015 | → |
| Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma. | Chastain EC et al. | — | 2015 | → |
| Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression. | Sutton LA et al. | — | 2015 | → |
| Clustering of Expression Data in Chronic Lymphocytic Leukemia Reveals New Molecular Subdivisions. | Yepes S et al. | — | 2015 | → |
| Computational characterisation of cancer molecular profiles derived using next generation sequencing. | Oleksiewicz U et al. | — | 2015 | → |
| Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. | Davids MS et al. | — | 2015 | → |
| Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. | Trimarco V et al. | — | 2015 | → |
| Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. | Hus I et al. | — | 2015 | → |
| Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. | Lucas DM et al. | — | 2015 | → |
| Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. | Sutton LA et al. | — | 2015 | → |
| Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. | Yin CC et al. | — | 2015 | → |
| De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia. | El-Ghammaz AM et al. | — | 2015 | → |
| Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. | Malcikova J et al. | — | 2015 | → |
| Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. | Salaverria I et al. | — | 2015 | → |
| Developing Molecular Signatures for Chronic Lymphocytic Leukemia. | Cornet E et al. | — | 2015 | → |
| DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies. | Shatnyeva OM et al. | — | 2015 | → |
| DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia. | Wang LQ et al. | — | 2015 | → |
| Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. | Zent CS et al. | — | 2015 | → |
| Emerging therapies for refractory chronic lymphocytic leukemia. | Kutsch N et al. | — | 2015 | → |
| Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. | Visco C et al. | — | 2015 | → |
| Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. | Ferrajoli A et al. | — | 2015 | → |
| Exome sequence read depth methods for identifying copy number changes. | Kadalayil L et al. | — | 2015 | → |
| Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. | Cavallini C et al. | — | 2015 | → |
| Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia. | Lapierre M et al. | — | 2015 | → |
| Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. | Stephens DM et al. | — | 2015 | → |
| Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. | Lanasa MC et al. | — | 2015 | → |
| Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. | Xia Y et al. | — | 2015 | → |
| Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. | Smith EN et al. | — | 2015 | → |
| Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. | Guièze R et al. | — | 2015 | → |
| Genomic landscape of liposarcoma. | Kanojia D et al. | — | 2015 | → |
| High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. | Reljic T et al. | — | 2015 | → |
| High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. | Jain P et al. | — | 2015 | → |
| How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? | Tam CS et al. | — | 2015 | → |
| Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. | Bowen DA et al. | — | 2015 | → |
| Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. | Maura F et al. | — | 2015 | → |
| Isochromosome 17q in Chronic Lymphocytic Leukemia. | Alhourani E et al. | — | 2015 | → |
| Jumping translocations, a novel finding in chronic lymphocytic leukaemia. | Miller CR et al. | — | 2015 | → |
| Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. | Sciumè M et al. | — | 2015 | → |
| Management of chronic lymphocytic leukemia. | Stilgenbauer S et al. | — | 2015 | → |
| Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors. | Mato A et al. | — | 2015 | → |
| Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. | Yang K et al. | — | 2015 | → |
| microRNA and Chronic Lymphocytic Leukemia. | Giza DE et al. | — | 2015 | → |
| Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. | Shahjahani M et al. | — | 2015 | → |
| Molecular pathogenesis of CLL and its evolution. | Rodríguez D et al. | — | 2015 | → |
| Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. | Strati P et al. | — | 2015 | → |
| Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. | Rodríguez D et al. | — | 2015 | → |
| Non-coding recurrent mutations in chronic lymphocytic leukaemia. | Puente XS et al. | — | 2015 | → |
| Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. | Brown JR et al. | — | 2015 | → |
| Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. | Prinz C et al. | — | 2015 | → |
| OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. | Liu TM et al. | — | 2015 | → |
| Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. | Innis-Shelton RD et al. | — | 2015 | → |
| Pathology of B-cell lymphomas: diagnosis and biomarker discovery. | Ondrejka SL et al. | — | 2015 | → |
| Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. | Cuesta-Mateos C et al. | — | 2015 | → |
| Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. | Kharfan-Dabaja MA | — | 2015 | → |
| Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. | Guièze R et al. | — | 2015 | → |
| Principles for the organization of gene-sets. | Li W et al. | — | 2015 | → |
| Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma. | Sun C et al. | — | 2015 | → |
| Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. | Hurtado AM et al. | — | 2015 | → |
| Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10(9)/L monoclonal lymphocytes better identifies subgroups with different outcomes. | Oliveira AC et al. | — | 2015 | → |
| Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia. | Yepes S et al. | — | 2015 | → |
| Role of microRNA in chronic lymphocytic leukemia onset and progression. | Balatti V et al. | — | 2015 | → |
| Role of miR-15/16 in CLL. | Pekarsky Y et al. | — | 2015 | → |
| Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. | Jean GW et al. | — | 2015 | → |
| Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. | Strati P et al. | — | 2015 | → |
| So FCR, so good. | Dearden C | — | 2015 | → |
| SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers. | Roisman A et al. | — | 2015 | → |
| TACI expression and signaling in chronic lymphocytic leukemia. | Mamara A et al. | — | 2015 | → |
| Targeting ATM-deficient CLL through interference with DNA repair pathways. | Knittel G et al. | — | 2015 | → |
| Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. | Opel D et al. | — | 2015 | → |
| TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. | Balatti V et al. | — | 2015 | → |
| Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. | Dos Santos P et al. | — | 2015 | → |
| The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. | Langerbeins P et al. | — | 2015 | → |
| The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. | Sutton LA et al. | — | 2015 | → |
| The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. | Davids MS et al. | — | 2015 | → |
| The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications. | Strefford JC | — | 2015 | → |
| The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? | Yang SM et al. | — | 2015 | → |
| The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. | Wiestner A | — | 2015 | → |
| The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. | Gutjahr JC et al. | — | 2015 | → |
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. | Byrd JC et al. | — | 2015 | → |
| TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. | Mongini PK et al. | — | 2015 | → |
| Understanding cancer cell survival is key to patient survival. | Fegan C et al. | — | 2015 | → |
| Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. | Yeh YY et al. | — | 2015 | → |
| Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. | Kasar S et al. | — | 2015 | → |
| Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. | Heinig K et al. | — | 2014 | → |
| Added predictive value of omics data: specific issues related to validation illustrated by two case studies. | De Bin R et al. | — | 2014 | → |
| Advances in treating chronic lymphocytic leukemia. | Tausch E et al. | — | 2014 | → |
| A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. | Shindiapina P et al. | — | 2014 | → |
| A new prognostic score for CLL. | Tam CS et al. | — | 2014 | → |
| Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. | Te Raa GD et al. | — | 2014 | → |
| B-cell receptor stereotypy and chronic lymphocytic leukaemia. | Michallet AS et al. | — | 2014 | → |
| Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. | Dietlein F et al. | — | 2014 | → |
| Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms? | García-Muñoz R et al. | — | 2014 | → |
| Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality. | Elyamany G et al. | — | 2014 | → |
| Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. | Baliakas P et al. | — | 2014 | → |
| Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH). | Alhourani E et al. | — | 2014 | → |
| Copy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphoma. | Conde L et al. | — | 2014 | → |
| CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL). | Liaw FP et al. | — | 2014 | → |
| Detection of clonal aberrations by cytogenetic analysis after different culture methods and by FISH in 129 patients with Chronic Lymphocytic Leukemia. | Jenderny J et al. | — | 2014 | → |
| Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. | Gragert L et al. | — | 2014 | → |
| Five hematologic tests and treatments to question. | Hicks LK et al. | — | 2014 | → |
| Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. | Delgado J et al. | — | 2014 | → |
| Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients. | Van Damme M et al. | — | 2014 | → |
| How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation. | Huang BT et al. | — | 2014 | → |
| Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia. | Chung C et al. | — | 2014 | → |
| Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia. | Collado R et al. | — | 2014 | → |
| Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. | Gentile M et al. | — | 2014 | → |
| Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. | Lin K et al. | — | 2014 | → |
| Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response. | Pierceall WE et al. | — | 2014 | → |
| Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. | Simonetti G et al. | — | 2014 | → |
| Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53. | Zent CS et al. | — | 2014 | → |
| NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. | Chiaretti S et al. | — | 2014 | → |
| Novel targets for ATM-deficient malignancies. | Winkler J et al. | — | 2014 | → |
| Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. | Mewawalla P et al. | — | 2014 | → |
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. | Burger JA et al. | — | 2014 | → |
| Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia. | Labib HA et al. | — | 2014 | → |
| Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? | McClanahan F et al. | — | 2014 | → |
| Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. | Wang J et al. | — | 2014 | → |